Latest Content

Adding Xofigo to Xtandi extends survival and delays disease progression in men with metastatic castration-resistant prostate cancer with bone involvement.

CAPItello-281 shows Truqap plus Zytiga extends rPFS in PTEN-deficient mHSPC with manageable toxicity and preserved overall quality of life.

Subcutaneous Rybrevant plus Keytruda led to a 56% response rate in recurrent or metastatic head and neck cancer in OrigAMI-4.

FDA approved Hernexeos for untreated HER2-mutant NSCLC after 76% of patients had tumor shrinkage in clinical trial data.

The landscape of relapsed or refractory multiple myeloma (RRMM) treatment is shifting toward a more targeted future, as Dr. Sagar Lonial explained.

The bispecific ADC izalontamab brengitecan improved survival for patients with metastatic triple-negative breast cancer in a Phase 3 clinical trial.

Daily practices help one writer find calm and stability while living with multiple myeloma.

Experts share what patients should know from the 2026 ASCO GU Cancer Symposium, highlighting biomarkers, trial options and personalized care decisions.

The OriGAMI-4 trial reveals subcutaneous Rybrevant's 45% response rate in metastatic head and neck cancer patients after immunotherapy and platinum.

Olympians’ resilience and joy offer lessons in strength and support for patients with cancer.

The FDA placed a partial hold on a phase 2 lorigerlimab trial in gynecologic cancers after a patient died from grade 4 neutropenia and septic shock.

Oncologists highlight key 2026 ASCO GU studies in bladder, prostate, kidney and testicular cancers that could reshape treatment and personalize care.

In a trial of 171 women, app-based self-acupressure improved fatigue vs usual care, offering a low-cost option for ovarian cancer survivors.